A 78-year-old man with Parkinson's disease presents with a 3-month history of intensely pruritic urticarial plaques on his flexures and groin, now followed by tense bullae that do not rupture easily. Direct immunofluorescence of perilesional skin shows linear IgG and C3 deposits along the basement membrane zone. He is not on any recent medications that might trigger blistering. The treatment approach marked **A** in the diagram is recommended as first-line management. Which of the following BEST explains why this regimen is preferred for his condition?
A. It has been demonstrated in landmark trials to achieve disease control with lower systemic toxicity and mortality compared to oral corticosteroids alone, particularly in elderly patients
B. It permanently restores hemidesmosomal integrity by upregulating collagen XVII expression and preventing further autoimmune attack
It directly neutralizes circulating IgG autoantibodies against BP180 and BP230, preventing complement activation at the basement membrane zone
C.
D. It suppresses the recruitment and activation of neutrophils and eosinophils at the dermal–epidermal junction, preventing protease-mediated cleavage of the lamina lucida
Explanation
Why option 3 is correct
The Joly et al. (NEJM 2002) landmark trial demonstrated that potent topical corticosteroids (clobetasol 0.05%) are superior to oral prednisone as first-line therapy for bullous pemphigoid, particularly in elderly patients, achieving better disease control with fewer systemic side effects and lower mortality. This evidence-based approach directly reflects the clinical anchor: topical clobetasol ± doxycycline + nicotinamide is the gold-standard first-line regimen for localized and generalized BP. The mechanism works by suppressing the inflammatory cascade (neutrophil and eosinophil recruitment) that mediates the subepidermal split, while avoiding the systemic complications of high-dose oral corticosteroids in an elderly population.
Why each distractor is wrong
Option 1: While BP is mediated by IgG autoantibodies against BP180 and BP230, topical corticosteroids do not directly neutralize circulating antibodies. This describes a mechanism more consistent with intravenous immunoglobulin or rituximab, not the first-line topical approach.
Option 2: Although suppression of neutrophil and eosinophil recruitment is part of the mechanism, this is not the PRIMARY reason topical corticosteroids are preferred over oral therapy. The key advantage is superior efficacy with lower systemic toxicity in elderly patients, not the mechanism of action alone.
Option 4: Topical corticosteroids do not restore hemidesmosomal integrity or upregulate collagen XVII. They suppress inflammation; they do not reverse the underlying autoimmune pathology or structural damage.
High-YieldNEET PG
Joly trial (NEJM 2002): topical clobetasol 0.05% is superior to oral prednisone in BP, especially in elderly patients—lower mortality, fewer systemic complications.
Joly P et al. NEJM 2002; Bolognia Dermatology 4th ed
Practice similar questions
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.
